Arcturus Therapeutics Holdings/$ARCT
1D1W1MYTD1Y5YMAX
Capital at risk
About Arcturus Therapeutics Holdings
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.
- Ticker
- $ARCT
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 109
- Headquarters
- San Diego, United States
- Website
- arcturusrx.com
ARCT Metrics
BasicAdvanced
$456M
-
-$3.33
2.27
-
Price and volume
Market cap
$456M
Beta
2.27
52-week high
$24.17
52-week low
$5.50
Average daily volume
1.3M
Financial strength
Current ratio
5.879
Quick ratio
5.764
Long term debt to equity
0.11
Total debt to equity
0.133
Interest coverage (TTM)
-11,366.00%
Profitability
EBITDA (TTM)
-99.548
Gross margin (TTM)
-195.50%
Net profit margin (TTM)
-317.61%
Operating margin (TTM)
-348.32%
Effective tax rate (TTM)
0.00%
Revenue per employee (TTM)
$270,000
Management effectiveness
Return on assets (TTM)
-23.96%
Return on equity (TTM)
-46.31%
Valuation
Price to revenue (TTM)
15.304
Price to book
2.65
Price to tangible book (TTM)
2.65
Price to free cash flow (TTM)
-6.172
Free cash flow yield (TTM)
-16.20%
Free cash flow per share (TTM)
-2.597
Growth
Revenue change (TTM)
-75.95%
Earnings per share change (TTM)
49.84%
3-year revenue growth (CAGR)
-51.93%
3-year earnings per share growth (CAGR)
3.97%
What the Analysts think about ARCT
Analyst ratings (Buy, Hold, Sell) for Arcturus Therapeutics Holdings stock.
Analyst projections of the future price of Arcturus Therapeutics Holdings stock.
Bulls say / Bears say
ARCT-810 has completed Phase II enrolment and dosing, with data and a regulatory plan expected in the third quarter. That creates a near-term clinical and regulatory catalyst for Arcturus's liver rare-disease platform. (Morningstar, The Motley Fool)
ARCT-032's Phase II cystic-fibrosis study remains on schedule, with enrolment continuing in the United States, Israel and Turkey. If the data supports Phase III, Thermo Fisher will provide manufacturing and clinical-research support, including up to $40 million of contributions, reducing the programme's funding burden. (Morningstar, Stock Analysis)
Arcturus ended June with $191.5 million in cash and says its resources should fund operations through the end of 2028. The CSL settlement added $12 million in cash and released about $16 million of liabilities and R&D credits, giving the company time to reach important rare-disease milestones without an immediate financing need. (Arcturus Therapeutics, RTTNews)
Second-quarter revenue fell to $3.0 million from $28.3 million a year earlier, while the net loss widened to $23.8 million from $9.2 million. The drop reflects the wind-down of the CSL Seqirus collaboration, leaving Arcturus with a much smaller near-term revenue base. (Arcturus Therapeutics, RTTNews)
Regaining KOSTAIVE gives Arcturus control, but also shifts future vaccine development, manufacturing, commercialisation and related funding responsibilities back to the company. CSL's exit also leaves Arcturus needing to rebuild partnerships or commercial infrastructure for a portfolio that previously had a major industry partner. (Arcturus Therapeutics, AllSci)
The investment case still depends on unproven Phase II programmes, and management says its existing capital would not realistically fund two independent Phase III trials. If both ARCT-810 and ARCT-032 advance, Arcturus may need a partner or new financing, which could limit economics or dilute shareholders. (MarketBeat, Stock Analysis)
Data summarised monthly by Lightyear AI. Last updated on 17 Sept 2026.
ARCT Financial Performance
Revenues and expenses
ARCT Earnings Performance
Company profitability
Upcoming events
No upcoming events
ARCT News
AllArticlesVideos
Arcturus Therapeutics Eyes Phase III CF Call, OTC Data as Vaccine Funds Pipeline
MarketBeat1 month ago
Arcturus Therapeutics Q2 Earnings Call Highlights
MarketBeat1 month ago
Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on Aug 6, 2026
Business Wire2 months ago
Funds containing ARCT
AllUSDGBPEUR
Fund name | Fund size | $ARCT weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.03% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.03% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.